Page last updated: 2024-12-05

triethylenemelamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triethylenemelamine: Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5799
CHEMBL ID502384
CHEBI ID27919
SCHEMBL ID8359
MeSH IDM0021951

Synonyms (102)

Synonym
AB00641911-02
2,4,6-tris(aziridin-1-yl)-[1,3,5]triazine
2,4,6-tri(1-aziridinyl)-1,3,5-triazine
2,4,6-tris(1-aziridinyl)-1,3,5-triazine
2,4,6-tris(aziridin-1-yl)-1,3,5-triazine
CHEBI:27919 ,
2,4,6-tri(aziridin-1-yl)-1,3,5-triazine
NCIMECH_000144
NCI60_042167
2,4,6-tris(1'-aziridinyl)-1,3,5-triazine
s-triazine, 2,4,6-tris(1-aziridinyl)-
trisethyleneimino-1,3,5-triazine
2,4,6-tris(ethylenimino)-s-triazine
hsdb 4000
triaethylenmelamin [german]
ai3-25296
einecs 200-083-5
2,4,6-triethyleneimino-s-triazine
brn 0242245
tretamina [inn-spanish]
ccris 613
2,4,6-tris(ethyleneimino)-s-triazine
tretaminum [inn-latin]
nsc 9706
2,4,6-tri(ethyleneimino)-1,3,5-triazine
2,4,6-triethylenimino-s-triazine
1,1',1''-s-triazine-2,4,6-triyltrisaziridine
aziridine, 1,1',1''-s-triazine-2,4,6-triyltris-
2,4,6-triethylenimino-1,3,5-triazine
m 9500
tretamin
tem (cytostatic)
persistol ho 1/193
TEM ,
sk #1133
1,5-triazine, 2,4,6-tris(1-aziridinyl)-
2,6-tri(ethylenimino-1,3,5-triazine
m-9500 ,
nsc9706 ,
2,6-tri(ethyleneimino)-1,3,5-triazine
1,1''-s-triazine-2,4,6-triyltrisaziridine
triethanomelamine
2,6-tri(ethyleneimino)-s-triazine
tem-simes
2,6-tri(ethylenimino-s-trazine
aziridine,1',1''-s-triazine-2,4,6-triyltris-
2,6-tris(1-aziridinyl)-s-triazine
r-246
persistol hoe 1/193
sk 1133
wln: t6n cn enj b- at3ntj& d- at3ntj& f- at3ntj
triamelin
triaziridinyl triazine
drp 859025
2,6-tris(ethyleneimino)-s-triazine
tretamine
2,6-tris(ethylenimino)-s-triazine
tris(ethyleneimino)triazine
s-triazine,4,6-tris(1-aziridinyl)-
persistol
nsc-9706
r 246
ent 25,296
2,6-tris(1-aziridinyl)-1,3,5-triazine
melamine, triethylene-
1,3,5-triazine, 2,4,6-tris(1-aziridinyl)-
triethylenemelamine
trisaziridinyltriazine
51-18-3
C07642
2,4,6-tris(1-aziridinyl)-s-triazine
triethylene melamine
CHEMBL502384
inchi=1/c9h12n6/c1-2-13(1)7-10-8(14-3-4-14)12-9(11-7)15-5-6-15/h1-6h2
iucjmvbfzdhpdx-uhfffaoysa-
CCG-35428
tretaminum
unii-f7iy6hzg9d
triethylenemelamine [nf]
tretamina
tretamine [inn]
triaethylenmelamin
f7iy6hzg9d ,
AKOS015907094
triethylenemelamine [hsdb]
tretamine [mart.]
tretamine [who-dd]
triethylenemelamine [mi]
2,4,6-tris(1-aziridinyl)-s-triazine [iarc]
1,3,5-triazine, 2,4,6-tris(1-aziridinyl)-.
SCHEMBL8359
2,4,6-tri(ethylenimino)-s-triazine
IUCJMVBFZDHPDX-UHFFFAOYSA-N
2,4,6-tri(ethylenimino)-1,3,5-triazine
2,4,6-tri(1-aziridinyl)-1,3,5-triazine #
2,4,6-tri(ethyleneimino)-s-triazine
DTXSID3026225
SR-01000941587-1
sr-01000941587
DB14031
Q7841462
A871352

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" CAR values of offspring of triethylenemelamine-treated males mated 4 wk after dosing were significantly higher than those of controls."( Conditioned avoidance responses of young mice and offspring of mice treated with neuroleptic or mutagenic agents.
Balazs, T; Petersen, KW; Yen-Koo, HC, 1978
)
0.55
" Dosage level is distinctly related to radiation complications, especially retinal vascular necrosis and fatal radiation-induced neoplasms."( Retinoblastoma.
Ellsworth, RM, 1977
)
0.26
" Highter TEM dosage increased the rate of embryonic loss."( [Investigations on the mutagenic effect of triethylenemelamine (TEM) on early embryonic tissue and bone marrow of the rat by chromosome analysis (author's transl)].
Grawit, G; Michelmann, HW; Paufler, S; Sterner, W, 1975
)
0.52
" Mean coefficients of variation of the G1 peaks were increased in both the low and high dosage groups relative to controls."( Flow-cytometric analysis of the effects of triethylenemelamine on somatic and testicular tissues of the rat.
Bickham, JW; Burton, DW; McBee, K; Sawin, VL, 1992
)
0.55
" In addition to the high mean MPE frequency observed after 2 doses of 116 mg/kg of PC at the 48-h sampling time, a late increase in micronucleus induction was also seen after triple dosing at the 96-h sampling time."( Comparison of single/multiple-dose protocols using triethylenemelamine and procarbazine hydrochloride for the mouse bone marrow micronucleus test.
Romagna, F; Schneider, BM,
)
0.38
" In the second study, effects from five dosage levels were measured at 1, 4, and 10 wk, and the highest dosage level was evaluated over 44 wk."( Long-term effects of triethylenemelamine exposure on mouse testis cells and sperm chromatin structure assayed by flow cytometry.
Baer, RK; Evenson, DP; Jost, LK, 1989
)
0.6
" The pattern of effects on spermatocytes, unlike midspermatids and early spermatozoa, indicated possible cytotoxic damage, so for the determination of TEM dose-response curves in the induction of genetic damage only the data for midspermatids and early spermatozoa were used."( Effects of dose on the induction of dominant-lethal mutations with triethylenemelamine in male mice.
Generoso, WM; Matter, BE, 1974
)
0.49
" Time-response and dose-response were studied for chromosomal aberrations induced by transplacental treatment of mouse embryos."( New approaches to mutagenicity studies in animals for carcinogenic and mutagenic agents. II. Clastogenic effects determined in transplacentally treated mouse embryos.
Adler, ID, 1983
)
0.27
"1 M solution of TEM was used to treat conidial suspensions of H-12 for 20, 40, 80, 120, or 170 min to obtain dose-response curves for (1) inactivation of conidia, and (2) the induction of specific-locus mutations in the ad-3 region."( Triethylenemelamine: induction of specific-locus mutations in the ad-3 region of heterokaryon 12 of Neurospora crassa.
de Serres, FJ; Malling, HV, 1995
)
1.73
" Timing and dosage are also considered."( SOME PROBLEMS IN THE CHEMOTHERAPY OF SOLID TUMOURS.
ARONOVITCH, M; GROSZMAN, M; KAHANA, LM, 1964
)
0.24
" Although small-molecule microarrays are a promising platform for miniaturized screening, it has been a challenge to use them to obtain quantitative dose-response curves in vitro, especially for lipophilic compounds."( Quantitative dose-response curves from subcellular lipid multilayer microarrays.
Chadwick, BP; Darrow, EM; Davidson, MW; Kusi-Appiah, AE; Lenhert, S; Lowry, TW; Wilson, KA, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
insect sterilantA chemosterilant intended to sterilize insects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1,3,5-triazinesAny compound with a 1,3,5-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 3 and 5 of the core benzene ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (612)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990583 (95.26)18.7374
1990's19 (3.10)18.2507
2000's3 (0.49)29.6817
2010's7 (1.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.99 (24.57)
Research Supply Index6.52 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.45%)5.53%
Reviews14 (2.08%)6.00%
Case Studies8 (1.19%)4.05%
Observational0 (0.00%)0.25%
Other647 (96.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]